Envoy Medical reported a narrower third quarter 2026 loss than anticipated, despite revenue of $66 thousand missing the consensus estimate of $420 thousand. Management is focused on clinical milestones for its Acclaim fully implanted cochlear implant, noting that the full 56-patient pivotal trial cohort has now surpassed the six-month follow-up milestone, keeping the company on track for a final FDA submission in 2027.
Key Highlights
- Clinical progress was highlighted by initial trial participants achieving a mean CNC word recognition score of 53.2% at 12 months, up from a 15.2% pre-implantation baseline.
- Regulatory advancement continued with the submission of the second modular PMA application to the FDA, with the final module containing total clinical data planned for mid-2027.
- Financial liquidity improved to $14.6 million in cash at quarter-end, following approximately $27.4 million in net financing proceeds during the period.